KR102376603B1 - 제니스테인 포스페이트 콘쥬게이트의 조성물의, 골량의 감소와 관련된 질환의 치료 또는 예방을 위한 사용 및 골 구조 및 골의 생체역학 강도를 개선하기 위한 사용 - Google Patents

제니스테인 포스페이트 콘쥬게이트의 조성물의, 골량의 감소와 관련된 질환의 치료 또는 예방을 위한 사용 및 골 구조 및 골의 생체역학 강도를 개선하기 위한 사용 Download PDF

Info

Publication number
KR102376603B1
KR102376603B1 KR1020180153710A KR20180153710A KR102376603B1 KR 102376603 B1 KR102376603 B1 KR 102376603B1 KR 1020180153710 A KR1020180153710 A KR 1020180153710A KR 20180153710 A KR20180153710 A KR 20180153710A KR 102376603 B1 KR102376603 B1 KR 102376603B1
Authority
KR
South Korea
Prior art keywords
bone
composition
day
genistein
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020180153710A
Other languages
English (en)
Korean (ko)
Other versions
KR20190067695A (ko
Inventor
왕 샹-타
쒸 쳔
쑤 난-웨이
Original Assignee
휴즈 바이오테크놀로지 컴퍼니 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 휴즈 바이오테크놀로지 컴퍼니 리미티드 filed Critical 휴즈 바이오테크놀로지 컴퍼니 리미티드
Publication of KR20190067695A publication Critical patent/KR20190067695A/ko
Application granted granted Critical
Publication of KR102376603B1 publication Critical patent/KR102376603B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/52—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an inorganic compound, e.g. an inorganic ion that is complexed with the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicinal Preparation (AREA)
KR1020180153710A 2017-12-07 2018-12-03 제니스테인 포스페이트 콘쥬게이트의 조성물의, 골량의 감소와 관련된 질환의 치료 또는 예방을 위한 사용 및 골 구조 및 골의 생체역학 강도를 개선하기 위한 사용 Active KR102376603B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762595697P 2017-12-07 2017-12-07
US62/595,697 2017-12-07

Publications (2)

Publication Number Publication Date
KR20190067695A KR20190067695A (ko) 2019-06-17
KR102376603B1 true KR102376603B1 (ko) 2022-03-18

Family

ID=64559585

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020180153710A Active KR102376603B1 (ko) 2017-12-07 2018-12-03 제니스테인 포스페이트 콘쥬게이트의 조성물의, 골량의 감소와 관련된 질환의 치료 또는 예방을 위한 사용 및 골 구조 및 골의 생체역학 강도를 개선하기 위한 사용

Country Status (6)

Country Link
US (1) US10881634B2 (https=)
EP (1) EP3494973B1 (https=)
JP (1) JP7029172B2 (https=)
KR (1) KR102376603B1 (https=)
CN (1) CN109939118A (https=)
TW (1) TWI756495B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025117337A1 (en) * 2023-11-28 2025-06-05 GreenStone Biosciences, Inc. Genistein phosphate derivatives
CN118359663B (zh) * 2024-04-26 2024-12-13 西安交通大学医学院第一附属医院 线粒体靶向染料木素衍生物及其在制备抗心肌缺血再灌注损伤药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999063995A1 (en) * 1998-06-12 1999-12-16 Vyrex Corporation Isoflavone derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6541613B2 (en) * 2000-12-15 2003-04-01 Uyrex Corporation Isoflavone derivatives
JP2007511542A (ja) * 2003-11-18 2007-05-10 ノボゲン リサーチ ピーティーワイ リミテッド イソフラボノイドプロドラッグ、その組成物、それらを使用する治療法
EP2182957A4 (en) * 2007-07-31 2012-07-18 Limerick Biopharma Inc PHOSPHORYLATED PYRONANALOGES AND CORRESPONDING METHODS
TR201004464A2 (tr) * 2010-06-03 2012-11-21 B�Lg�� Mahmut Kemik erimesi için formülasyon.
US8900635B2 (en) * 2010-11-15 2014-12-02 Humanetics Corporation Nanoparticle isoflavone compositions and methods of making and using the same
CN102351828A (zh) * 2011-08-16 2012-02-15 李荣立 一种提取金雀异黄素的新工艺
CN102488210B (zh) * 2011-12-27 2013-06-19 西南大学 染料木素水凝胶的复合物及其制备方法
CN105381470B (zh) * 2015-11-27 2018-11-02 广东医科大学 一种改性染料木素及其应用
TWI670374B (zh) * 2016-04-25 2019-09-01 國立臺灣大學 具有苯並吡喃酮類磷酸酯合成酶活性之多肽、包含編碼該多肽之核酸序列之微生物及苯並吡喃酮類磷酸酯衍生物之製備方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999063995A1 (en) * 1998-06-12 1999-12-16 Vyrex Corporation Isoflavone derivatives

Also Published As

Publication number Publication date
EP3494973A1 (en) 2019-06-12
JP2019099579A (ja) 2019-06-24
TW201924691A (zh) 2019-07-01
EP3494973B1 (en) 2021-07-28
CN109939118A (zh) 2019-06-28
US10881634B2 (en) 2021-01-05
US20190175545A1 (en) 2019-06-13
KR20190067695A (ko) 2019-06-17
TWI756495B (zh) 2022-03-01
JP7029172B2 (ja) 2022-03-03

Similar Documents

Publication Publication Date Title
KR20020084230A (ko) 호르몬 보충요법
US10792324B2 (en) Compositions and methods for the treatment of orthopedic ailments
KR102376603B1 (ko) 제니스테인 포스페이트 콘쥬게이트의 조성물의, 골량의 감소와 관련된 질환의 치료 또는 예방을 위한 사용 및 골 구조 및 골의 생체역학 강도를 개선하기 위한 사용
JP2003095971A (ja) 骨粗鬆症治療剤または組成物
CN109771424B (zh) 一种防治老年ⅱ型糖尿病性骨质疏松症的药物组合物及其应用
HUT64848A (en) Medical preparatives for preventing and treating osteoporises after menopausa
JP3604710B2 (ja) 骨粗鬆症予防及び治療剤
WO2006135121A1 (en) Bone disease drug composition using herb medicines
CN104587470A (zh) 一种促进骨质疏松性骨折术后骨愈合的药物组合物及其应用
JPH06211682A (ja) 内分泌系上昇剤
CN112137087A (zh) 一种壮骨补钙的组合物、保健品及其制备方法
CN110876766A (zh) 牡丹籽油在制备改善男性骨生物力学性能的药品及保健食品的应用
CN109289038A (zh) 一种组合物及其制备方法和应用
JP2010275309A (ja) エルデカルシトールを含有する重症骨粗鬆症患者での非外傷性椎体骨折抑制剤
Hale et al. Exploring the role of progestins and phytoestrogens in menopause
JP5627081B2 (ja) 骨粗鬆症予防・治療剤及び健康食品
DOWNEY Thwart POST-MEAL Bloating and Indigestion
US11058737B2 (en) Use of Euycoma longifolia extract in alleviating symptoms and/or conditions associated with hormonal imbalance in females
KR102125740B1 (ko) 텍토리게닌 7-0-자일로실글루코시드를 포함하는 여성 갱년기 증상 완화용 조성물
Nguyen et al. Tibia Bone and Soft Tissue Characteristics in Oral Contraceptive Users and Non-Users: 2485 Board# 149 May 31 11: 00 AM-12: 30 PM
JP3752344B2 (ja) 抗骨粗鬆症剤
WO2021065661A1 (ja) 筋肉量の低下抑制、低下予防、維持、回復又は増加用組成物
KR20220064039A (ko) 척수 손상 예방 또는 치료용 조성물
CN111357979A (zh) 抑制高脂引起的肥胖及骨丢失的保健食品组合物及其应用
KR20220032874A (ko) 2,4,6-트리페닐-1-헥센을 유효성분으로 포함하는 골질환 예방 또는 치료용 조성물

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
A302 Request for accelerated examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PA0302 Request for accelerated examination

St.27 status event code: A-1-2-D10-D17-exm-PA0302

St.27 status event code: A-1-2-D10-D16-exm-PA0302

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 5